Genmab — Februar 2018
-
Analytiker vil sætte Genmabs prognose under lup
Fokus vil være på forventningerne til 2018, når Genmab onsdag fremlægger årsregnskab, mener Jyske Banks analytiker Frank Hørning Andersen.
(medwatch.dk)
-
-
new:
A Trial of Tisotumab Vedotin in Cervical Cancer - https://clinicaltrials.gov/ct2/show/NCT03438396?term=Tisotumab&rank=2 -
Science Report: Unexpected immune activation illustrated in the cold - in collaboration with Genmab, interesting science - https://www.uu.nl/en/news/unexpected-immune-activation-illustrated-in-the-cold
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
